The NEMO study tested a treatment for neonatal seizures.

What is NEMO?

NEMO stands for "Treatment of NEonatal seizures with Medication Off-patent: evaluation of efficacy and safety of bumetanide."

The NEMO study aimed to devleop a way of treating seizures in newborns. Our researchers evaulated bumetanide, an antiepileptic drug. 

Metabolomic Lab Work
How did NEMO work?

NEMO was the first antiepileptic drug specifically aimed at this newborn age-group. The trial used EEG monitoring in a large, randomised  method which represented the gold standard for seziure diagnosis in the newborn.

newborn swaddled

NEMO was an FP7 funded project.

Subscribe to our newsletter